$4.840
-0.020 (-0.41%)Zum Schluss
IVA-News
IVA-Events
Inventiva Completes Final 72-Week Visit in NATiV3 Trial
Inventiva announced the last patient has completed their final 72-week visit in the NATiV3 Phase 3 clinical trial evaluating lanifibranor for the treatment of patients with MASH with moderate and advanced fibrosis.
Inventiva Appoints Chris Benecchi as COO
Inventiva announced the appointment of Chris Benecchi as COO. Benecchi will lead Inventiva's operational readiness as the company approaches its NATiV3 Phase 3 topline study results of lanifibranor, in MASH, expected in Q4, and prepares for potential commercialization. Most recently, he served as CEO of Motric Bio.
Draganfly Borrow Rate Increases to 15.28%
Latest data shows the largest indicative borrow rate increases among liquid option names include: Draganfly (DPRO) 15.28% +2.94, KULR Technology Group (KULR) 26.19% +2.30, Defiance Daily Target 2x Long OKLO ETF (OKLL) 15.06% +2.17, REalloys Inc (ALOY) 49.95% +1.81, Sunbelt Rentals Holdings Inc (SUNB) 2.29% +1.48, Canadian Solar (CSIQ) 3.41% +0.70, Global X CyberSecurity ETF (BUG) 2.97% +0.53, Quantum Computing (QUBT) 14.07% +0.52, Inventiva SA (IVA) 1.67% +0.49, and MSOX ETF (MSOX) 5.04% +0.42.
Inventiva Appoints New Leadership Team Members
Inventiva (IVA) announced three new members of its leadership team: Axel-Sven Malkomes as CFO, Susan Coles as chief legal officer, and Pamela Herbster as chief people officer. Former CFO Jean Volatier will transition to the role of EVP finance and corporate social responsibility, where he will continue to support the company on strategic priorities. Malkomes was most recently CFO at publicly CureVac (CVAC). Coles comes to Inventiva from Vivet Therapeutics, where she was head of legal and finance. Herbster comes to Inventiva from Sage Therapeutics, where she led both human resources and business operations.
Inventiva Prices 32.47M Share Spot Secondary at $3.85
Leerink and Piper Sandler acted as joint book running managers for the offering.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.